Clearside Biomedical/CLSD

$1.25

0.76%
-
1D1W1MYTD1YMAX

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.

Ticker

CLSD

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

George Lasezkay

Employees

30

Headquarters

Alpharetta, United States

CLSD Metrics

BasicAdvanced
$93.4M
Market cap
-
P/E ratio
-$0.53
EPS
2.36
Beta
-
Dividend rate
$93.4M
2.35526
$2.12
$0.65
357.01K
4.421
-76.15%
-89.34%
11.354
519.89%
3.8%
1.38%

What the Analysts think about CLSD

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 6 analysts.
340% upside
High $8.00
Low $4.00
$1.25
Current price
$5.50
Average price target

CLSD Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-76.19% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$6.3M
687.5%
Net income
$-4.8M
-47.83%
Profit margin
-76.19%
-93.37%

CLSD Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 8.57%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.15
-$0.15
-$0.15
-$0.08
-
Expected
-$0.14
-$0.14
-$0.16
-$0.09
-$0.14
Surprise
7.14%
5.88%
-3.23%
-8.57%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Clearside Biomedical stock?

Clearside Biomedical (CLSD) has a market cap of $93.4M as of April 14, 2024.

What is the P/E ratio for Clearside Biomedical stock?

The price to earnings (P/E) ratio for Clearside Biomedical (CLSD) stock is 0 as of April 14, 2024.

Does Clearside Biomedical stock pay dividends?

No, Clearside Biomedical (CLSD) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next Clearside Biomedical dividend payment date?

Clearside Biomedical (CLSD) stock does not pay dividends to its shareholders.

What is the beta indicator for Clearside Biomedical?

Clearside Biomedical (CLSD) has a beta rating of 2.36. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Clearside Biomedical stock price target?

The target price for Clearside Biomedical (CLSD) stock is $5.5, which is 340% above the current price of $1.25. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Clearside Biomedical stock

Buy or sell Clearside Biomedical stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing